High-dose chemotherapeutics of intravesical chemotherapy rapidly induce mitochondrial dysfunction in bladder cancer-derived spheroids

Cancer Science

Volumn 106, Issue 1, 2015, Pages 69-77

  Yoshida, Takahiro ^a,b   Okuyama, Hiroaki ^a   Nakayama, Masashi ^a   Endo, Hiroko ^a   Nonomura, Norio ^b   Nishimura, Kazuo ^a   Inoue, Masahiro ^a,c  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

3 D culture; Bladder cancer; Cell death; Chemosensitivity; Intravesical chemotherapy

Indexed keywords

DNA; EPIRUBICIN; MITOMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER TISSUE ORIGINATED SPHEROID; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DISTRIBUTION; DRUG MEGADOSE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; TRANSURETHRAL RESECTION; TUMOR SPHEROID; ANIMAL; CANCER TRANSPLANTATION; DNA FRAGMENTATION; DRUG EFFECTS; INTRAVESICAL DRUG ADMINISTRATION; MALE; MITOCHONDRION; MULTICELLULAR SPHEROID; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; TUMOR CELL CULTURE; URINARY BLADDER NEOPLASMS;

ADMINISTRATION, INTRAVESICAL; ANIMALS; ANTINEOPLASTIC AGENTS; DNA FRAGMENTATION; EPIRUBICIN; HUMANS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE, INBRED NOD; MICE, SCID; MITOCHONDRIA; MITOMYCIN; NEOPLASM TRANSPLANTATION; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 84923221402     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12567     Document Type: Article

References (44)

1. American Cancer Society. Cancer Facts and Figures 2014. [Cited 21 May 2014.] Available from URL: http://www.cancer.org/acs/groups/content/atresearch/documents/webcontent/acspc-042151.pdf.
2. Parekh DJ, Bochner BH, Dalbagni G. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J Clin Oncol 2006; 24: 5519-27.
3. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003; 21: 1315-30.
4. Avritscher EB, Cooksley CD, Grossman HB et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006; 68: 549-53.
5. Sievert KD, Amend B, Nagele U et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009; 27: 295-300.
6. Sylvester RJ, Oosterlinck W, van der Meijden APM. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage ta t1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171: 2186-90.
7. Perlis N, Zlotta AR, Beyene J, Finelli A, Fleshner NE, Kulkarni GS. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. Eur Urol 2013; 64: 421-30.
8. Brocks CP, Buttner H, Bohle A. Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer. J Urol 2005; 174: 1115-8.
9. Akaza H, Kurth KH, Williams R et al. Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future direction. Urol Oncol 1998; 4: 121-9.
10. Pan JS, Slocum HK, Rustum YM, Greco WR, Gaeta JF, Huben RP. Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder. J Urol 1989; 142: 1589-93.
11. Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993; 149: 749-52.
12. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005; 5: 231-7.
13. Vanlangenakker N, Vanden Berghe T, Vandenabeele P. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ 2012; 19: 75-86.
14. Zoli W, Ricotti L, Tesei A et al. Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro. Clin Cancer Res 2004; 10: 1500-7.
15. Chen SK, Chung CA, Cheng YC et al. Hydrostatic pressure enhances mitomycin C induced apoptosis in urothelial carcinoma cells. Urol Oncol 2014; 32: e17-24.
16. Maruyama T, Higuchi Y, Suzuki T, Qiu J, Yamamoto S, Shima H. Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells. J Infect Chemother 2011; 17: 11-6.
17. Gazzaniga P, Silvestri I, Gradilone A et al. Gemcitabine-induced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer. Anticancer Drugs 2007; 18: 179-85.
18. Yeung TK, Germond C, Chen X, Wang Z. The mode of action of taxol: apoptosis at low concentration and necrosis at high concentration. Biochem Biophys Res Commun 1999; 263: 398-404.
19. Torres K, Horwitz SB. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 1998; 58: 3620-6.
20. Bolenz C, Ikinger EM, Strobel P et al. Topical chemotherapy in human urothelial carcinoma explants: a novel translational tool for preclinical evaluation of experimental intravesical therapies. Eur Urol 2009; 56: 504-11.
21. Burgues JP, Gomez L, Pontones JL, Vera CD, Jimenez-Cruz JF, Ozonas M. A chemosensitivity test for superficial bladder cancer based on three-dimensional culture of tumour spheroids. Eur Urol 2007; 51: 962-9. discussion 9-70.
22. Kondo J, Endo H, Okuyama H et al. Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc Natl Acad Sci U S A 2011; 108: 6235-40.
23. Endo H, Okami J, Okuyama H et al. Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation. J Thorac Oncol 2013; 8: 131-9.
24. Okuyama H, Yoshida T, Endo H et al. Involvement of heregulin/HER3 in the primary culture of human urothelial cancer. J Urol 2013; 190: 302-10.
25. Galluzzi L, Vitale I, Abrams JM et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19: 107-20.
26. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700-14.
27. Duchen MR. Roles of mitochondria in health and disease. Diabetes 2004; 53 (Suppl 1): S96-102.
28. Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 2013; 38: 209-23.
29. Jackson SP, Schoenwaelder SM. Procoagulant platelets: are they necrotic? Blood 2010; 116: 2011-8.
30. Lopez-Erauskin J, Galino J, Bianchi P et al. Oxidative stress modulates mitochondrial failure and cyclophilin D function in X-linked adrenoleukodystrophy. Brain 2012; 135: 3584-98.
31. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004; 18: 1272-82.
32. Ricci MS, Zong WX. Chemotherapeutic approaches for targeting cell death pathways. Oncologist 2006; 11: 342-57.
33. Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 2007; 13: 7271-9.
34. Kreuzaler P, Watson CJ. Killing a cancer: what are the alternatives? Nat Rev Cancer 2012; 12: 411-24.
35. Linkermann A, Green DR. Necroptosis. New Engl J Med 2014; 370: 455-65.
36. Tsujimoto Y. Apoptosis and necrosis: intracellular ATP level as a determinant for cell death modes. Cell Death Differ 1997; 4: 429-34.
37. Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 2004; 16: 663-9.
38. Tsujimoto Y, Shimizu S. Role of the mitochondrial membrane permeability transition in cell death. Apoptosis 2007; 12: 835-40.
39. Nakagawa T, Shimizu S, Watanabe T et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005; 434: 652-8.
40. Bryan RT, Tselepis C. Cadherin switching and bladder cancer. J Urol 2010; 184: 423-31.
41. Gunther JH, Jurczok A, Wulf T et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res 1999; 59: 2834-7.
42. Bohle A, Jurczok A, Ardelt P et al. Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo. J Urol 2002; 167: 357-63.
43. Pode D, Alon Y, Horowitz AT, Vlodavsky I, Biran S. The mechanism of human bladder tumor implantation in an in vitro model. J Urol 1986; 136: 482-6.
44. Kaasinen E, Rintala E, Hellstrom P et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 2002; 42: 167-74.